Summary Retrospective studies have recently demonstrated a significant correlation between dose intensity of chemotherapy and response rates and survival in various diseases including epithelial ovarian carcinoma. As part of a proposed randomised trial to assess the effect of dose intensity on outcome in ovarian carcinoma, a pilot study has been undertaken to determine the toxicity and efficacy of the high intensity therapy. Nineteen patients with advanced ovarian carcinoma received initial treatment with cisplatin 120 mg m2 i.v. day 1, and cyclophosphamide 1,000 mg 2 i.v. day 1, given at 21-day intervals for six cycles. The average relative dose intensity of this therapy is 1.14 when compared with the CHAP regimen. Severe toxicity was experienced by most patients. The median received average relative dose intensity was 0.90, with only one patient receiving treatment to the proposed intensity. Randomised studies of the effect of dose intensity in ovarian carcinoma are essential, but an initial step must be to assess whether the proposed high dose treatment can be delivered.
Cisplatin-based chemotherapy is widely accepted as the standard treatment for advanced epithelial ovarian carcinoma. It produces higher response rates compared with single alkylating agents, although its effect on survival is less clear (Gynaecological Group: Clinical Oncology Society of Australia, 1986; Bruckner et al., 1981; Decker et al., 1982; Williams et al., 1985; Vogl, 1983) . In recent studies, high dose chemotherapy regimens (mainly with cisplatin) have been used in an attempt to improve response rates (Ozols et al., 1985) . Such intensive regimens are associated with considerable toxicity, often requiring long periods of inpatient care. It is therefore essential that such regimens are compared with less intensive therapy in a systematic fashion. Levin and Hryniuk (1987) have analysed dose intensity (dose per unit time) in studies of chemotherapy in ovarian cancer and have suggested a correlation between dose intensity, response rate and median survival. An apparent survival advantage was demonstrated for combination chemotherapy (especially cisplatin based) compared with single agents. The significance of the correlation is unclear since the study was retrospective and many of the patients included in the trials were highly selected. In addition, the analysis of dose intensity was based upon the planned and not the received dose intensity.
For these reasons we decided to undertake a prospective randomised study to test the effect upon survival of chemotherapy with cisplatin and cyclophosphamide at two dose intensities, but to the same total dose, in patients with advanced ovarian carcinoma. Before this, we decided to carry out a phase II study of the high dose intensity chemotherapy in an unselected patient population. Our aims were to assess its toxicity and to determine whether the planned dose intensity could be attained. 2. For renal impairment, creatinine clearance was determined from the serum creatinine using the method of Cockcroft and Gault (1976) . If this value was borderline for treatment (see below), the glomerular filtration rate was determined by radiolabelled technetium clearance. If the creatinine clearance was greater than 70 1 24 h-' (50 ml min-') full dose cisplatin was given. If the creatinine clearance was 50-701 24 h-' (30-50 ml min-'), 50% of doses of cisplatin were given. If the creatinine clearance was less than 50 1 24 h-' 30 ml min -'), cisplatin was omitted.
Calculation of average relative dose intensity This was calculated according to the method of Levin and Hryniuk (1987) , using the CHAP regimen, as described by Greco et al. (1981) , as the standard regimen with an average relative dose intensity (ARDI) of 1. Briefly, the method is as follows. The dose intensity of individual drugs is calculated in a standardised form of mg m-2week-'. Each dose intensity is then calculated as a decimal fraction of the intensity of the respective drug in the standard regimen, giving the relative dose intensity of each drug. The relative dose intensities are then added and divided by 4 (the number of drugs in the CHAP regimen) to produce the ARDI. Since the study regimen has less than four drugs, the two 'missing' drugs are assigned to relative dose intensity of zero.
Thus, the planned ARDI of the study regimen is: 40/15+330/175+0+0 = 1.14 4
Received ARDIs were calculated by the same method, accounting for dose reduction and treatment delays. Patients in whom one or more cycles of treatment were omitted because of toxicity were still assumed to have a total treatment period of 18 weeks. However, patients in whom treatment was omitted because of progressive disease were assessed on the basis of the actual number of weeks on treatment, calculated to the date on which the next cycle of treatment would have been due.
Assessment of toxicity and response
Toxicities were recorded according to WHO criteria. As well as alopecia, nausea and vomiting and haematological toxicity, particular attention was paid to renal toxicity, ototoxicity and peripheral neuropathy.
Response was assessed after two cycles of chemotherapy and 4 weeks after the completion of chemotherapy. This included physical examination and repetition of previously abnormal investigations. Second look laparotomy was not performed in any patient.
Definition of responses was as follows: complete response, no clinical or radiological evidence of disease; partial response, >50% reduction in the product of the two largest perpendicular diameters of any measurable lesion; stable disease, <50% reduction in the product of the two largest perpendicular diameters of any measurable lesion; progressive disease, increase in measurable disease at known sites or appearance of new lesions. oedema of both lower limbs during pre-hydration for her first cycle of chemotherapy. This was due to inferior vena cava compression and the patient was treated with alternative chemotherapy.
In Peripheral neuropathy was particularly common, occurring in 12 patients. This has persisted over several months in surviving patients and has been present, but improving, for 9 months after completion of chemotherapy.
Results
Nineteen patients were entered into this study. Details of their characteristics at presentation are shown in Table I (Levin & Hryniuk, 1987 (Bronchud et al., 1988) . Although such agents would clearly be of potential advantage, the dose-limiting toxicity of carboplatin is thrombocytopenia, and none of the currently available recombinant haemopoietic growth factors have been shown to produce significant improvement in platelet counts in humans. Nevertheless, the use of such factors might allow the dose of classical alkylating agents in such regimens to be increased. An alternative method of achieving a higher dose intensity is the inclusion of more drugs with differing doselimiting toxicities, as used in regimens such as CHAP. However, comparisons of two-and four-drug regimens are difficult, and a major criticism of Levin and Hryniuk's method of calculating ARDI is that is assumes that all of the drugs in a particular combination have equivalent anti-tumour activity. In at least two studies (Barker & Wiltshaw, 1981 ; Gruppo Interegionale Cooperativo Oncologico Ginecologia, 1987) the inclusion of doxorubicin into cisplatin/alkylating agent combinations failed to produce improved response rates or survival. Neijt et al. (1987) , in a prospective randomised study, have demonstrated that a cisplatin/cyclophosphamide (CP) combination was equivalent to the CHAP-5 regimen in terms of response, progression-free survival and overall survival. Furthermore, although nephrotoxicity was more severe in the CP arm, other toxicities, including myelosuppression and neurotoxicity were more frequent in patients given the fourdrug combinations.
To attempt to overcome the problems of comparison of such regimens, we have analysed the dose intensities in our study using the CP regimen described above as the standard with an ARDI of 1.0. Using this method, the planned ARDI of our regimen is 1.5, and the median received ARDI is 1.18. A direct comparison of the outcome for patients in our study and the trial of Neijt et al. (1987) is, of course, impossible. However, it is noteworthy that although the received ARDI for our patients is higher than the planned ARDI of CP in the study of Neijt et al. (and therefore higher than their received ARDI -the percentages of total planned doses given were 94% for cisplatin and 83% for cyclophosphamide), the overall response rates were identical, at 67%.
In view of the small number of patients, and short followup, no comment can be made regarding the outcome for the study group. The clinical CR rate (10/18) is disappointing, but this may be because most patients had bulky disease postoperatively. It is noteworthy that most had >2 cm residual disease after laparotomy.
For those patients analysed for ARDI, a median value of 0.90 was attained, approaching the projected dose intensity of the CHAP regimen. However, two of our patients had received ARDIs of less than 0.4.
Prospective randomised studies of the effect of dose intensity on survival in ovarian carcinoma are essential if the effect of dose intensity is to be properly assessed. Based on our results, we believe that an initial step in any such study should be to test whether the high dose intensity chemotherapy can be delivered. Although we were unable to attain the projected ARDI in this study, that achieved might be suitable as the high intensity arm of a randomised study.
